Keyword: Samsung BioLogics
China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.
Samsung BioLogics lost almost $6 billion in market value after South Korean securities regulators said the company broke accounting rules.
Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.
GSK is asked for more about its China bribery scandal, AZ made two health-tech deals in China, Samsung BioLogics' reported sales growth.
South Korea’s Samsung BioLogics reported a 56% jump in sales to $420 million (KRW 459.8 billion) for 2017, which the company attributes to boosts from two of its manufacturing facilities.
J&J's diabetes unit attracts Chinese buyers, Novartis and Biocon form a biosimilar deal, plus Keytruda-Lenvima combo gets a breakthrough tag.
Samsung is tamping down investor excitement about a fourth biologics manufacturing site after one of its execs suggested it could be built sooner.
China’s WuXi Biologics says its new $150 million, 30,000-liter capacity biologics plant is up and running, a feat it accomplished in less than three years.
Daiichi reported results from a troubled cancer trial and formed a deal with Glycotope, Samsung BioLogics reported operating profits.
Merck KGaA and South Korea’s Samsung BioLogics are deepening a collaboration even as Samsung reported an operating profit for the first time.